Abstract
In people living with HIV (PLWH), immune compromise is largely due to a decrease in CD4 + T-lymphocyte (CD4) cells, resulting in increased rates of human immunodeficiency virus (HIV)-associated morbidity and mortality as CD4 + cell count declines. Previously, it was common to defer initiation of antiretroviral therapy (ART) in asymptomatic PLWH until their CD4 + cell count declined below a certain threshold, which has changed throughout the years based on updated guidelines, increasing access to ART, and lower drug prices.
Accepted Version (Free)
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have